SINEMET CR
CARBIDOPA; LEVODOPA
Approval overview SINEMET CR is listed in Drugs@FDA under application 019856 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient CARBIDOPA; LEVODOPA Form and strength TABLET, EXTENDED RELEASE;ORAL - 50MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ORGANON LLC Submission history Latest submission status date: 2026-03-19 00:00:00.
Structured Monograph
Clinical summary
Approval overview SINEMET CR is listed in Drugs@FDA under application 019856 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CARBIDOPA; LEVODOPA Form and strength TABLET, EXTENDED RELEASE;ORAL - 50MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ORGANON LLC Submission history Latest submission status date: 2026-03-19 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.